GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » E10

NeuBase Therapeutics (NeuBase Therapeutics) E10 : $-145.68 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

NeuBase Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was $-0.660. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-145.68 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average E10 Growth Rate was 0.80% per year. During the past 5 years, the average E10 Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of NeuBase Therapeutics was 0.80% per year. The lowest was -49.20% per year. And the median was -7.85% per year.

As of today (2024-06-09), NeuBase Therapeutics's current stock price is $0.378. NeuBase Therapeutics's E10 for the quarter that ended in Sep. 2023 was $-145.68. NeuBase Therapeutics's Shiller PE Ratio of today is .


NeuBase Therapeutics E10 Historical Data

The historical data trend for NeuBase Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics E10 Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -143.90 -149.23 -148.01 -154.07 -145.88

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.09 -148.11 -149.82 -147.99 -145.68

Competitive Comparison of NeuBase Therapeutics's E10

For the Biotechnology subindustry, NeuBase Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Shiller PE Ratio falls into.



NeuBase Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeuBase Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.66/129.8595*129.8595
=-0.660

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 -40.000 98.326 -52.828
201403 -40.000 99.695 -52.103
201406 -36.000 100.560 -46.489
201409 -52.000 100.428 -67.239
201412 -72.000 99.070 -94.377
201503 -48.000 99.621 -62.570
201506 -44.000 100.684 -56.750
201509 -52.000 100.392 -67.264
201512 -80.000 99.792 -104.104
201603 -68.000 100.470 -87.891
201606 -96.000 101.688 -122.596
201609 -84.000 101.861 -107.089
201612 -84.000 101.863 -107.087
201703 -84.000 102.862 -106.047
201706 -28.000 103.349 -35.182
201709 -32.000 104.136 -39.905
201712 -29.600 104.011 -36.956
201803 -15.400 105.290 -18.994
201806 -3.800 106.317 -4.641
201809 -44.929 106.507 -54.780
201812 -6.400 105.998 -7.841
201903 -8.000 107.251 -9.686
201906 -8.000 108.070 -9.613
201909 -26.887 108.329 -32.231
201912 -5.200 108.420 -6.228
202003 -5.200 108.902 -6.201
202006 -3.600 108.767 -4.298
202009 -4.000 109.815 -4.730
202012 -3.600 109.897 -4.254
202103 -4.800 111.754 -5.578
202106 -5.800 114.631 -6.570
202109 -4.200 115.734 -4.713
202112 -4.800 117.630 -5.299
202203 -6.000 121.301 -6.423
202206 -5.200 125.017 -5.401
202209 -4.800 125.227 -4.978
202212 -2.600 125.222 -2.696
202303 -2.400 127.348 -2.447
202306 -2.040 128.729 -2.058
202309 -0.660 129.860 -0.660

Add all the adjusted EPS together and divide 10 will get our e10.


NeuBase Therapeutics  (NAS:NBSE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


NeuBase Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801